carbamates has been researched along with Pneumonia, Viral in 10 studies
Pneumonia, Viral: Inflammation of the lung parenchyma that is caused by a viral infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All these compounds not only showed excellent pharmacokinetic properties, absorption, metabolism, minimal toxicity and bioavailability but were also remain stabilized at the active site of proteins during the MD simulation." | 1.56 | Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. ( Bhowmik, D; Jagadeesan, R; Kumar, D; Kumar, N; Nandi, R; Prakash, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YW | 2 |
| Yiu, CB | 2 |
| Wong, KY | 2 |
| Sayad, B | 1 |
| Sobhani, M | 1 |
| Khodarahmi, R | 1 |
| Izzi, A | 1 |
| Messina, V | 1 |
| Rinaldi, L | 1 |
| Maggi, P | 1 |
| Bhowmik, D | 1 |
| Nandi, R | 1 |
| Jagadeesan, R | 1 |
| Kumar, N | 1 |
| Prakash, A | 1 |
| Kumar, D | 1 |
| Iftikhar, H | 1 |
| Ali, HN | 1 |
| Farooq, S | 1 |
| Naveed, H | 1 |
| Shahzad-Ul-Hussan, S | 1 |
| Lens, S | 1 |
| Miquel, M | 1 |
| Mateos-Muñoz, B | 1 |
| García-Samaniego, J | 1 |
| Forns, X | 1 |
| Abbaspour Kasgari, H | 1 |
| Moradi, S | 1 |
| Shabani, AM | 1 |
| Babamahmoodi, F | 1 |
| Davoudi Badabi, AR | 1 |
| Davoudi, L | 1 |
| Alikhani, A | 1 |
| Hedayatizadeh Omran, A | 1 |
| Saeedi, M | 1 |
| Merat, S | 2 |
| Wentzel, H | 3 |
| Garratt, A | 2 |
| Levi, J | 2 |
| Simmons, B | 3 |
| Hill, A | 3 |
| Tirgar Fakheri, H | 1 |
| Sadeghi, A | 2 |
| Ali Asgari, A | 1 |
| Norouzi, A | 1 |
| Kheiri, Z | 1 |
| Anushirvani, A | 1 |
| Montazeri, M | 1 |
| Hosamirudsai, H | 1 |
| Afhami, S | 1 |
| Akbarpour, E | 1 |
| Aliannejad, R | 1 |
| Radmard, AR | 1 |
| Davarpanah, AH | 1 |
| Qavi, A | 1 |
| Eslami, G | 1 |
| Mousaviasl, S | 1 |
| Radmanesh, E | 1 |
| Jelvay, S | 1 |
| Bitaraf, S | 1 |
| Freeman, J | 1 |
| Salmanzadeh, S | 1 |
| Esmaeilian, H | 1 |
| Mobarak, M | 1 |
| Tabibi, R | 1 |
| Jafari Kashi, AH | 1 |
| Lotfi, Z | 1 |
| Talebzadeh, SM | 1 |
| Wickramatillake, A | 1 |
| Momtazan, M | 1 |
| Hajizadeh Farsani, M | 1 |
| Marjani, S | 1 |
| Mobarak, S | 1 |
| Ju, J | 1 |
| Li, X | 1 |
| Kumar, S | 1 |
| Jockusch, S | 1 |
| Chien, M | 1 |
| Tao, C | 1 |
| Morozova, I | 1 |
| Kalachikov, S | 1 |
| Kirchdoerfer, RN | 1 |
| Russo, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial[NCT04498936] | Phase 4 | 240 participants (Actual) | Interventional | 2020-07-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for carbamates and Pneumonia, Viral
| Article | Year |
|---|---|
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug T | 2020 |
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug T | 2020 |
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug T | 2020 |
7 other studies available for carbamates and Pneumonia, Viral
| Article | Year |
|---|---|
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
Topics: Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus 3C Proteases; Coronavirus Infections; COVID | 2020 |
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Clinical Trials as Topic; Coronavirus Infections; COV | 2020 |
Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; DNA-Directed DNA Po | 2020 |
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Topics: Amides; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Binding Sites; Caffeic Acids; Carbam | 2020 |
Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
Topics: Amides; Betacoronavirus; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus Infections; | 2020 |
SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain.
Topics: Antiviral Agents; Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dru | 2020 |
Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
Topics: Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dideoxynucleotides; | 2020 |